

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete If Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number

09/699,003

RECEIVED

OCT 14 2003

Filing Date

October 26, 2000

TECHNOLOGY CENTER F3700

First Named Inventor

M. Rigdon Lentz

Group Art Unit

3762

Examiner Name

P. Bianco

Sheet

2

of

3

Attorney Docket Number

LEN 101 CIP CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	7 ²
BM		ADERKA, et al., "Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients," <i>Cancer Res.</i> 51: 5602-5607 (1991).	
		AMIT, et al., "Three-dimensional structure of an antigen-antibody complex at 2.8 resolution," <i>Science</i> 233: 747-751 (1986).	
		CLACKSON, et al., "Making of antibody fragments using phage display libraries," <i>Nature</i> 352: 624-688 (1991).	
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19: 2471-2476 (1991).	
		DIGEL, et al., "High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia," <i>J. Clin. Invest</i> 89: 1690-1693 (1992).	
		ELSÄSSER-BEILE, et al., "Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients," <i>Tumor Biol.</i> 15: 17-24 (1993).	
		EY, et al., "Isolation of pure IgG ₁ , IgG _{2a} , and IgG _{2b} immunoglobins from mouse serum using protein A-Sepharose," <i>Immunochemistry</i> 15:429-436 (1978).	
		KABAT, et al., eds., <i>Sequences of Proteins of Immunological Interest</i> , 4 th ed., U.S Dept. Health & Human Services: Bethesda, MD (1987).	
		KESSLER, "Adsorptive plasma treatment: optimization of extracorporeal devices and systems," <i>Blood Purif.</i> 11: 150-157 (1993).	
QUP		LENTZ, et al., "Low molecular weight protein apheresis and regression of breast cancer," <i>Jpn. J. Apheresis</i> 16(1): 107-114 (1997).	

Examiner's Signature	<i>P. Bianco</i>	Date Considered	2-2-04
----------------------	------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

RECEIVED

OCT 14 2003

TECHNOLOGY CENTER R3700

Application Number 09/699,003
Filing Date October 26, 2000
First Named Inventor M. Rigdon Lentz
Group Art Unit 3762
Examiner Name P. Bianco
Attorney Docket Number LEN 101 CIP CON

Sheet 3 of 3

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PMB		PANKA, et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <i>Proc. Natl. Acad. Sci. USA</i> 85: 3080-3084 (1988).	
		RUDIHOFF, et al., "Single amino acid substitution altering antigen-binding specificity," <i>Immunology</i> 79: 1979-1983 (1982).	
		SELINSKY & HOWELL, "Soluble tumor necrosis factor receptor type I enhances tumor development and persistence <i>in vivo</i> ," <i>Cell. Immunol.</i> 200: 81-87 (2000).	
PMB		SELINSKY, "Dissertation: The role of soluble tumor necrosis factor type I in tumor survival," Colorado State University, Fort Collins, Colorado (1999).	

Examiner's Signature *P. Bianco* Date Considered 2-2-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.